Email This Content
Send an email to a colleague about this document. Non-subscribers may purchase the article.© Copyright 2010 WINDHOVER INFORMATION INC., All Rights Reserved
Windhover Information Inc. - Health Care Business Intelligence
Delivering essential analysis and insights to top health care executives, investment professionals, and industry consultants
Netherlands-based sample and assay developer Qiagen is acquiring molecular diagnostics company Digene for $1.42bn in cash and stock.
For information about Strategic Transactions, Elsevier Business Intelligence's comprehensive database of biopharmaceutical, medical device and diagnostic dealmaking activity, please click here.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.
If you are already a subscriber, please log in for complete access. 
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.
Click an article title to see a free preview.
Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk, IN VIVO 1/1/2010
With DxS, Qiagen Moves into Personalized Medicine, IN VIVO 10/1/2009
The A-List: 2008's Trend Shaping Series A Financings, Start-Up 1/1/2009
Can Nanotech Be a Game-Changer for In Vitro Diagnostics?, Start-Up 11/1/2008
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q2 2007, IN VIVO 10/1/2007
